SignatureFD
AVBP icon

SignatureFD’s ArriVent BioPharma AVBP Stock Holding History

SignatureFD’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.1K Hold
368
– – ﹤0.01% 2679
2026
Q2 		$12.8K Hold
368
– – ﹤0.01% 2544
2026
Q1 		$8.49K Hold
368
– – ﹤0.01% 2575
2025
Q4 		$7.4K Hold
368
– – ﹤0.01% 2558
2025
Q3 		$6.79K Buy
368
+350
+1,944% +$6.88K ﹤0.01% 2542
2025
Q2 		$392 Buy
+18
New +$374 ﹤0.01% 3139

Other funds holding AVBP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

SignatureFD's AVBP Position: Q3 2026 in Review

SignatureFD held its ArriVent BioPharma (AVBP) position steady in Q3 2026 at 368 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2679.

SignatureFD first reported a position in AVBP in Q2 2025 and has held it in 6 quarters since. The position peaked at $12.8K in Q2 2026. 56 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • SignatureFD held 368 shares of ArriVent BioPharma worth $11.1K as of Q3 2026.
  • SignatureFD left its ArriVent BioPharma share count unchanged in Q3 2026.
  • ArriVent BioPharma made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2679 holding.
  • SignatureFD first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 6 quarters since.
  • SignatureFD's ArriVent BioPharma position peaked at $12.8K in Q2 2026.
  • 56 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.